Using advanced imaging technology and computational simulations, scientists have, for the first time, glimpsed the action of a cellular machine at work within living cells. The work puts forth a new concept of cellular machines as dynamic protein complexes that are continually building and rebuilding themselves within the cell, rather than the stable structures scientists have traditionally thought them to be.
A diet rich in flaxseed seems to reduce the size, aggressiveness and severity of tumors in mice that have been genetically engineered to develop prostate cancer, according to new research from Duke University Medical Center. And in 3 percent of the mice, the flaxseed diet kept them from getting the disease at all. “The amount of flaxseed given to each mouse was 5 percent of its total food intake, which would be a very difficult amount for humans to eat,” said a lead researcher. “[B]ut it does signal that we are on the right track and need to continue research in this area.”
Researchers in Leicester, England and Michigan will begin tests on a new cancer prevention drug, based on a natural compound found in red wine. The compound, resveratrol, is a natural agent found in grapes, peanuts and several berries. It is present in fruit juice from these berries and in wine. Consumption of resveratrol has been proposed as one possible explanation for the low incidence of cardiovascular disease in Southern European countries with high red wine consumption, and resveratrol has been shown to possess anti-inflammatory and anti-cancer activity in experimental models.
Researchers have discovered that a molecule best known for its anti-microbial properties also has the ability to activate key cells in the immune response. This newly discovered function suggests the molecule, a peptide called ?-defensin 2, may be useful in the development of more effective cancer vaccines.
Men who test positive for elevated prostate specific antigen (PSA) levels sometimes freak out because they think it means they have cancer. To find out, a surgeon will often perform a biopsy. But researchers from the National Cancer Institute and the Food and Drug Administration report that a new test using a single drop of blood could help distinguish between prostate cancer and benign conditions. The trick is identifying patterns of proteins found in patients’ blood serum.